Roth Capital Brokers Decrease Earnings Estimates for RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Ltd. (NASDAQ:RDHL) – Stock analysts at Roth Capital decreased their FY2018 earnings per share estimates for RedHill Biopharma in a report released on Monday. Roth Capital analyst S. Henry now forecasts that the brokerage will post earnings per share of ($2.00) for the year, down from their previous forecast of ($1.60).
A number of other research firms also recently commented on RDHL. Zacks Investment Research downgraded shares of RedHill Biopharma from a “hold” rating to a “sell” rating in a report on Friday, July 29th. HC Wainwright set a $33.00 price objective on shares of RedHill Biopharma and gave the company a “buy” rating in a report on Friday, October 7th. Finally, FBR & Co reiterated an “outperform” rating and issued a $36.00 price objective on shares of RedHill Biopharma in a report on Thursday, August 25th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $26.20.
RedHill Biopharma (NASDAQ:RDHL) traded down 1.62% during mid-day trading on Wednesday, hitting $14.04. 27,396 shares of the stock traded hands. RedHill Biopharma has a 12 month low of $8.10 and a 12 month high of $16.54. The stock has a 50-day moving average price of $14.60 and a 200-day moving average price of $12.82. The stock’s market cap is $178.79 million.
RedHill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings results on Wednesday, July 27th. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.52.
Several hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its stake in RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in RedHill Biopharma during the second quarter valued at $142,000. Ingalls & Snyder LLC purchased a new stake in RedHill Biopharma during the second quarter valued at $451,000. Finally, Van ECK Associates Corp boosted its stake in RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the period. 15.30% of the stock is owned by institutional investors and hedge funds.
About RedHill Biopharma
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.